JHTV is introducing the Innovator in Residence (IIR) program in collaboration with Emmett Cunningham, Jr., M.D., Ph.D., to further leverage the experience of external life sciences experts and enhance faculty education in early translational research and entrepreneurship. Dr. Cunningham will serve as the inaugural IIR and provide his guidance on advancing Johns Hopkins research with a primary focus on therapeutics.
We are currently building a team comprised of life sciences professionals willing to share their expertise with Johns Hopkins faculty and to be a part of the IIR program to support high-level, value-creating projects through accelerated innovation.
IIR Roles and Responsibilities
- Serve as an ad-hoc resource to Johns Hopkins faculty members with questions and concerns regarding innovation, product development and company creation
- Advise on or assist with the development of product development strategies
- Build internal and external support for faculty innovation and entrepreneurship
- Share best practices and industry knowledge on product development, company creation, partnership formation, and financing
- Provide expertise and guidance in preparation for investor discussions
- Identify market opportunities
- Participate as a guest lecturer or panelist related to faculty education, specific commercialization trends/projects, careers in innovation or appropriate topics
- Visit Baltimore four times a year for one to two days of selected meetings/educational sessions (including workshops, boot camps, lunch and learns, and panels)
- Host curated virtual monthly “office hours” for Johns Hopkins faculty members interested in innovation and entrepreneurship
- Participate in monthly calls with JHTV staff to provide feedback on the program’s progress and to help improve outreach and faculty support
About Emmett Cunningham, Jr., M.D., Ph.D.
A full-time entrepreneur and investor for more than 20 years, Dr. Cunningham retired at the end of 2023 from the Blackstone Group (BX), where he served as a Senior Managing Director from Nov. 2018 until March 2023, and subsequently as an Executive Advisor. Following his retirement from BX, he joined HealthQuest Capital Management as a Senior Partner and is currently on the Board of Galera Therapeutics. An internationally recognized specialist in infectious and inflammatory eye disease with over 400 publications, he received an M.D. and MPH in epidemiology and statistics from Johns Hopkins University and a Ph.D. in neuroscience from the University of California at San Diego for work done at The Salk Institute. Read full bio.